IP Library › Granted Patent US 12,269,825
Granted Patent B2
US 12,269,825 · App. 18/067,387 · Granted Apr 8, 2025

Organic compounds

Inventors: Sharon Mates (New York, NY); Peng Li (New Milford, NJ); Lawrence P. Wennogle (Hillsborough, NJ); Robert Davis (San Diego, CA)
Assignee: INTRA-CELLULAR THERAPIES, INC.
C07D471/16A61K31/4985A61K45/06A61P25/18A61P25/22A61P25/24C07B59/002C07D471/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,269,825
App. No.
18/067,387
Granted
Apr 8, 2025
Kind
B2
Abstract

This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT 2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D 1 /D 2 receptor signaling systems, and/or the treatment of residual symptoms.

Claims (22)

1. A pharmaceutical composition comprising a compound of formula I:

wherein:

R 1 is CH 3 ;

R 2 and R 3 are each independently H or D;

R 4 and R 5 are each H;

provided that R 2 and R 3 are not both H,

and wherein D is deuterium;

in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.

2. The composition according to claim 1 , wherein said compound is in pharmaceutically acceptable salt form.

3. The composition according to claim 2 , wherein the salt is selected from a group consisting of toluenesulfonic, fumaric and phosphoric acid addition salt.

4. A method for the treatment or prophylaxis of a central nervous system disorder comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 1 .

5. The method according to claim 4 , wherein said disorder is selected from a group consisting of obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, agitation, agitation in dementia, agitation in autism and related autistic disorders, post-traumatic stress disorder, impulse control disorders, and intermittent explosive disorder.

6. The method according to claim 4 , wherein said disorder is one or more disorders associated with dementia, selected from the group consisting of mild cognition impairment, senile dementia, Alzheimer's disease, Pick's disease, fronto-temporal dementia, parasupranuclear palsy, dementia with Lewy bodies, vascular dementia, Huntington's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Down syndrome, elderly depression, Wernicke-Korsakoff's syndrome, cortico-basal degenerations, autism, and attention deficit hyperactivity disorder.

7. The method according to claim 4 , wherein said disorder is a disorder involving one of the serotonin 5-HT 2A , dopamine D2 and/or serotonin reuptake transporter (SERT) pathways.

8. The method according to claim 4 , further comprising the administration of one or more other therapeutic agents.

9. The method according to claim 8 , wherein the one or more other therapeutic agents are selected from anti-depressive agents selected from compounds that modulate GABA activity, a GABA-B agonist, a 5-HT modulator, a melatonin agonist, an ion channel modulator, a serotonin-2 antagonist/reuptake inhibitor (SARIs), an orexin receptor antagonist, an H3 agonist, a noradrenergic antagonist, a galanin agonist, a CRH antagonist, human growth hormone, a growth hormone agonist, estrogen, an estrogen agonist, a neurokinin-1 drug, and antipsychotic agents, each in free or pharmaceutically acceptable salt form.

10. The method according to claim 8 , wherein the one or more other therapeutic agents are antipsychotic agents selected from chlorpromazine, haloperidol, droperidol, fluphenazine, loxapine, mesoridazine, molindone, perphenazine, pimozide, prochlorperazine, promazine, thioridazine, thiothixene, trifluoperazine, clozapine, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone, asenapine, lurasidone, iloperidone, cariprazine, amisulpride, zotepine, and sertindole, each in free or pharmaceutically acceptable salt form.

11. The method according to claim 8 , wherein the one or more other therapeutic agents are anti-depressive agents selected from one or more of amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine sulfate, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine.

12. The method according to claim 8 wherein the one or more other therapeutic agents are anti-depressive agents selected from selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants.

13. The method according to claim 12 , wherein the anti-depressive agent is a SSRI.

14. The method according to claim 5 , wherein the depression is refractory depression or major depressive disorder.

15. The method according to claim 5 , wherein the agitation in dementia is agitation in Alzheimer's disease.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2023
From: MATES, SHARON; LI, PENG; WENNOGLE, LAWRENCE P.; DAVIS, ROBERT E.
To: INTRA-CELLULAR THERAPIES, INC.
Reel/Frame 062943/0479 →
Continuity (6)
Continuation 17124224 · Dec 16, 2020
Continuation 16786240 · Feb 10, 2020
Continuation 16054728 · Aug 3, 2018
Continuation 15301912
Provisional Application 61975610 · Apr 4, 2014
Related Publication 20230203037A1 · Jun 29, 2023
References Cited (191)
US 2490813A · Hughes et al. · 1949 [cited by applicant]
US 3299078A · Pachter · 1967 [cited by applicant]
US 3813392A · Sellstedt et al. · 1974 [cited by applicant]
US 4001263A · Plattner et al. · 1977 [cited by applicant]
US 4136145A · Fuchs et al. · 1979 [cited by applicant]
US 4219550A · Rajagopalan · 1980 [cited by applicant]
US 4238607A · Rajagopalan · 1980 [cited by applicant]
US 4389330A · Tice et al. · 1983 [cited by applicant]
US 4530840A · Tice et al. · 1985 [cited by applicant]
US 4849246A · Schmidt · 1989 [cited by applicant]
US 5004602A · Hutchinson · 1991 [cited by applicant]
US 5114976A · Norden · 1992 [cited by applicant]
US 5151419A · Perenyi et al. · 1992 [cited by applicant]
US 5538739A · Bodmer et al. · 1996 [cited by applicant]
US 5576460A · Buchwald et al. · 1996 [cited by applicant]
US 5629003A · Horstmann et al. · 1997 [cited by applicant]
US 5648539A · Goodbrand · 1997 [cited by applicant]
US 5648542A · Goodbrand et al. · 1997 [cited by applicant]
US 5654482A · Goodbrand · 1997 [cited by applicant]
US 5705697A · Goodbrand et al. · 1998 [cited by applicant]
US 5723669A · Goodbrand et al. · 1998 [cited by applicant]
US 5723671A · Goodbrand et al. · 1998 [cited by applicant]
US 5763476A · Delbressine et al. · 1998 [cited by applicant]
US 5847166A · Buchwald et al. · 1998 [cited by applicant]
US 5902901A · Goodbrand et al. · 1999 [cited by applicant]
US 5948430A · Zerbe et al. · 1999 [cited by applicant]
US 6043370A · Kubo et al. · 2000 [cited by applicant]
US 6221335B1 · Foster · 2001 [cited by applicant]
US 6235936B1 · Buchwald et al. · 2001 [cited by applicant]
US 6307087B1 · Buchwald et al. · 2001 [cited by applicant]
US 6323366B1 · Wolfe et al. · 2001 [cited by applicant]
US 6395916B1 · Buchwald et al. · 2002 [cited by applicant]
US 6407092B1 · Hester et al. · 2002 [cited by applicant]
US 6419952B2 · Wong et al. · 2002 [cited by applicant]
US 6440710B1 · Keinan et al. · 2002 [cited by applicant]
US 6541639B2 · Zhou et al. · 2003 [cited by applicant]
US 6544559B2 · Mesens et al. · 2003 [cited by applicant]
US 6548493B1 · Robichaud et al. · 2003 [cited by applicant]
US 6552017B1 · Robichaud et al. · 2003 [cited by applicant]
US 6552024B1 · Chen et al. · 2003 [cited by applicant]
US 6603008B1 · Ando et al. · 2003 [cited by applicant]
US 6699852B2 · Robichaud et al. · 2004 [cited by applicant]
US 6713471B1 · Robichaud et al. · 2004 [cited by applicant]
US 6759554B2 · Buchwald et al. · 2004 [cited by applicant]
US 6762329B2 · Marcoux et al. · 2004 [cited by applicant]
US 6849619B2 · Robichaud et al. · 2005 [cited by applicant]
US 6849640B2 · Ennis et al. · 2005 [cited by applicant]
US 6888032B2 · Buchwald et al. · 2005 [cited by applicant]
US 7071186B2 · Robichaud et al. · 2006 [cited by applicant]
US 7081455B2 · Robichaud et al. · 2006 [cited by applicant]
US 7183282B2 · Robichaud et al. · 2007 [cited by applicant]
US 7223870B2 · Ghosh et al. · 2007 [cited by applicant]
US 7223879B2 · Buchwald et al. · 2007 [cited by applicant]
US RE39679E · Robichaud et al. · 2007 [cited by applicant]
US RE39680E · Robichaud et al. · 2007 [cited by applicant]
US 7238690B2 · Robichaud et al. · 2007 [cited by applicant]
US 7307091B2 · Alken et al. · 2007 [cited by applicant]
US 7517990B2 · Ito et al. · 2009 [cited by applicant]
US 7998971B2 · Barlow et al. · 2011 [cited by applicant]
US 8309722B2 · Tomesch et al. · 2012 [cited by applicant]
US 8414922B2 · Bryson et al. · 2013 [cited by applicant]
US 8461148B2 · Hollander · 2013 [cited by applicant]
US 8598119B2 · Mates et al. · 2013 [cited by applicant]
US 8603514B2 · Yang et al. · 2013 [cited by applicant]
US 8648077B2 · Tomesch et al. · 2014 [cited by applicant]
US 8652378B1 · Yang et al. · 2014 [cited by applicant]
US 8779139B2 · Tomesch et al. · 2014 [cited by applicant]
US 8791138B2 · Seeman et al. · 2014 [cited by applicant]
US 8835459B2 · Kottayil et al. · 2014 [cited by applicant]
US 8900497B2 · Yang et al. · 2014 [cited by applicant]
US 8900498B2 · Yang et al. · 2014 [cited by applicant]
US 8906277B2 · Yang et al. · 2014 [cited by applicant]
US 8993572B2 · Mates et al. · 2015 [cited by applicant]
US 9108340B2 · Yang et al. · 2015 [cited by applicant]
US 9168258B2 · Mates et al. · 2015 [cited by applicant]
US 9199995B2 · Tomesch et al. · 2015 [cited by applicant]
US 9216175B2 · Amancha et al. · 2015 [cited by applicant]
US 9315504B2 · Tomesch et al. · 2016 [cited by applicant]
US 9371324B2 · Mates et al. · 2016 [cited by applicant]
US 9393192B2 · Yam et al. · 2016 [cited by applicant]
US 9427412B2 · Bryson et al. · 2016 [cited by applicant]
US 9428506B2 · Mates et al. · 2016 [cited by applicant]
US 9586960B2 · Tomesch et al. · 2017 [cited by applicant]
US 9616061B2 · Mates et al. · 2017 [cited by applicant]
US 9708322B2 · Li et al. · 2017 [cited by applicant]
US 9745300B2 · Mates et al. · 2017 [cited by applicant]
US 9751883B2 · Tomesch et al. · 2017 [cited by applicant]
US 9956227B2 · Vanover et al. · 2018 [cited by applicant]
US 10072010B2 · Li et al. · 2018 [cited by applicant]
US 10077267B2 · Mates · 2018 [cited by examiner]
US 10117867B2 · Mates et al. · 2018 [cited by applicant]
US 10221176B2 · Tomesch et al. · 2019 [cited by applicant]
US 10245260B2 · Yao et al. · 2019 [cited by applicant]
US 10322134B2 · Vanover et al. · 2019 [cited by applicant]
US 10597394B2 · Mates · 2020 [cited by examiner]
US 10688097B2 · Yao · 2020 [cited by examiner]
US 10702522B2 · Mates et al. · 2020 [cited by applicant]
US 10716786B2 · Li et al. · 2020 [cited by applicant]
US 10899762B2 · Mates · 2021 [cited by examiner]
US 10960009B2 · Vanover et al. · 2021 [cited by applicant]
US 10960010B2 · Vanover et al. · 2021 [cited by applicant]
US 11026951B2 · Mates et al. · 2021 [cited by applicant]
US 11053245B2 · Mates et al. · 2021 [cited by applicant]
US 11096944B2 · Yao · 2021 [cited by examiner]
US 11124514B2 · Mates et al. · 2021 [cited by applicant]
US 11560382B2 · Mates · 2023 [cited by examiner]
US 11723909B2 · Yao · 2023 [cited by examiner]
US 20040142970A1 · Chung et al. · 2004 [cited by applicant]
US 20050222209A1 · Zeldis et al. · 2005 [cited by applicant]
US 20080132552A1 · Kleinman et al. · 2008 [cited by applicant]
US 20090076159A1 · Czarnik · 2009 [cited by applicant]
US 20090209608A1 · Czarnik · 2009 [cited by applicant]
US 20100159033A1 · Gant et al. · 2010 [cited by applicant]
US 20110269777A1 · Bachurin et al. · 2011 [cited by applicant]
US 20140080816A1 · Koolman et al. · 2014 [cited by applicant]
US 20160354315A1 · Li · 2016 [cited by applicant]
US 20200392135A1 · Wennogle et al. · 2020 [cited by applicant]
GB 1476087 · 1977 [cited by applicant]
WO WO2000064899 · 2000 [cited by applicant]
WO WO2014110322 · 2014 [cited by applicant]
WO WO2017117514 · 2017 [cited by applicant]
WO WO2018106916 · 2018 [cited by applicant]
Balbach, et al., “Pharmaceutical evaluation of early development candidates ‘the 100 mg-approach’”, [cited by applicant]
Barman et al., “Newer Antipsychotics: Brexpiprazole, Cariprazine, and Lumateperone: A Pledge or Another Unkept Promise?,” World J. Psychiatr., vol. 11, No. 12, p. 1228-38 (2021). [cited by applicant]
Bremner, et al., “Neuroimaging of Posttraumatic Stress Disorder”, [cited by applicant]
Browne, T.R., “Stable Isotope Techniques in Early Drug Development: An Economic Evaluation,” [cited by applicant]
Cherrah, et al., “Study of Deuterium Isotope Effects on Protein Binding by Gas Chromatography/Mass Spectrometry. Caffeine and Deuterated Isotopomers,” [cited by applicant]
Correll et al., “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia a Randomized Clinical Trial,” JAMA Psychiatry, vol. 77, No. 4, p. 349-358 (2020). [cited by applicant]
Darmani, et al., “Do Functional Relationships Exist Between 5-HT [cited by applicant]
Davis, et al., “ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers,” [cited by applicant]
Davis, et al., “ITI-007 in the Treatment of Schizophrenia: From Novel Pharmacology to Clinical Outcomes,” [cited by applicant]
Docherty et al., “Effect of Aripiprazole Versus Haloperidol on PANSS Prosocial Items in Early-Episode Patients with Schizophrenia,” Schizophrenia Res., vol. 120, p. 199-203 (2010). [cited by applicant]
Dyck, et al., “Effects of Deuterium Substitution on the Catabolismof ⊕-Phenylethylamine: An In Vivo Study,” [cited by applicant]
Edinoff et al., “Lumateperone for the Treatment of Schizophrenia,” Psychopharmacology Bulletin, vol. 50, No. 4, p. 32-59 (2020). [cited by applicant]
Ellenbroek et al., “Animal Models for the Negative Symptoms of Schizophrenia,” Behavioural Pharmacology, vol. 11, pp. 223-233, (2000). [cited by applicant]
Fletcher, P., et al., “Perceiving is Believing: A Bayesian Approach to Explaining the Positive Symptoms of Schizophrenia,” Nature Reviews/Neuroscience, vol. 10, pp. 48-58, (2009). [cited by applicant]
Foster et al., “Emerging Approaches for Treatment of Schizophrenia: Modulation of Cholinergic Signaling,” Discov. Med., vol. 14, No. 79, p. 413-420 (2012). [cited by applicant]
Gouyette, A., “Synthesis of Deuterium-labelled Elliptinium and its Use in Metabolic Studies,” Biomedical and Environmental Mass Spectrometry, vol. 15, pp. 243-247, (1988). [cited by applicant]
Gramigna, J, “Lumateperone Safe, Effective for Depressive Symptoms Among Patients with Bipolar Disorders,” American Society of Clinical Psychopharmacology Annual Meeting, Jun. 2, 2020, 3 pages. [cited by applicant]
Harbert, et al., “Neuroleptic Activity in 5-Aryltetrahydro-y-carbolines”, [cited by applicant]
Harvey, et al., “Lumateperone Improves Negative Symptoms Related to Emotional Experience (Avolition) in Patient with Schizophrenia,” Abstract presented at the American Society of Clinical Psychopharmacology (ASCP) Annua… [cited by applicant]
Haskins, N.J., “The Application of Stable Isotopes in Biomedical Research,” Biological Mass Spectrometry, vol. 9, No. 7, pp. 269-277, (1982). [cited by applicant]
Helfer et al., “Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis,” Am. J. Psychiatry, vol. 173, No. 9, p. 876-886 (2016). [cited by applicant]
Hlavinka, E., “Schizophrenia Tx Eases Depression in Bipolar Disorder: Lumateperone Offers Greater Rate of Response, Remission versus Placebo,” Medpage Today, 7 pages, (2020); https://www.medpagetoday.com/meetingcoverage… [cited by applicant]
Honma, et al., “The Metabolism of Roxatidine Acetate Hydrochloride: Liberation of Deuterium from the Piperidine Ring during Hydroxylation,” Drug Metabolism and Disposition, vol. 15, No. 4, pp. 551, (1987). [cited by applicant]
Howland, R.H., “Deuterated Drugs,” [cited by applicant]
Izrayelit, L., “Schizoaffective Disorder and PTSD Successfully Treated With Olanzapine and Supportive Psychotherapy”, [cited by applicant]
Kahn, A., et al., “Residual Symptoms of Schiziphrenia. What are Realistic Treatment Goals? Lingering Symptoms Require you to Evaluate Pharmacotherapy and Offer Psychosocial Interventions,” [cited by applicant]
Kay, et al., “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia,” [cited by applicant]
Kendrick, “The Newer, ‘Atypical’ Antipsychotic Drugs—Their Development and Current Therapeutic Use,” British J. General Practice, vol. 49, p. 745-749 (1999). [cited by applicant]
Khorana, et al., “Gamma-Carbolines: Binding at 5-HT5A Serotonin Receptors,” [cited by applicant]
Koppel, et al., “Optimal Treatment of Alzheimer's Disease Psychosis: Challenges and Solutions,” [cited by applicant]
Lammers, et al., “Risperidone Long-acting Injection in Schizophrenia Spectrum Illnesses Compared to First Generation Depot Antipsychotics in an Outpatient Setting in Canada,” BMC Psychiatry, vol. 13, No. 155, 9 pages, (… [cited by applicant]
Lee, et al. “Novel, Highly Potent, Selective 5-HT [cited by applicant]
Li, et al., “Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders,” [cited by applicant]
Lieberman, et al., “ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial,” [cited by applicant]
Lin, et al., “Dosage and Duration of Antipsychotic Treatment in Demented Outpatients with Agitation or Psychosis,” [cited by applicant]
Makadia et al., “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” Polymers (Basel), vol. 3, No. 3, pp. 1377-1397, (2011). [cited by applicant]
Marek et al. Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders. Neuropsychopharmacology, 2003. vol. 28, pp. 402-412. (2003). [cited by applicant]
Mass et al., “Psychopathological Syndromes of Schizophrenia: Evaluation of the Dimensional Structure of the Positive and Negative Syndrome Scale,” Schizophrenia Bull., vol. 26, No. 1, p. 167-177 (2000). [cited by applicant]
McConnell et al., “Modified-Release Oral Drug Delivery,” Aulton's Pharmaceutics, Chapter 31, pp. 550-565 (2013). [cited by applicant]
Medisorb Fact Sheet in Medisorb Microspheres Technology (Jan. 2009) at https://static.secure.website/wscfus/6472891/uploads/Medisorb.pdf (retrieved from the internet May 18, 2020) (2009). [cited by applicant]
Möller et al., “Pharmacological Treatment of Negative Symptoms in Schizophrenia,” Eur. Arch. Psychiatry Clin. Neurosci., vol. 265, p. 567-578 (2015). [cited by applicant]
Mueller, et al., “Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales,” Can J Psychiatry, vol. 51, No. 6, pp. 387-392, (2006). [cited by applicant]
Nihon rounen igaku zasshi, vol. 48, No. 3, pp. 195-204, (2011 nen). English translation only, 2 pages. [cited by applicant]
Palanisamy, M. et al., “Cellulose-Based Matrix Microspheres of Prednisolone Inclusion Complex; Preparation and Characterization.” American Association of Pharmaceutical Scientists PharmSciTech, vol. 12, No. 1, pp. 388-4… [cited by applicant]
Perlis et al., “Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials”, Am J Psychiatry, vol. 163, p. 225-231, (2006). [cited by applicant]
Pieniaszek, et al., “Moricizine Bioavailability via Simultaneous Dual, Stable Isotope Administration: Bioequivalence Implications,” [cited by applicant]
Press Release, “Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psyc… [cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Positive Top-Line Results from a Phase 3 Trial of Lumateperone in Patient with Bipolar Depression,” Intra-Cellular Therapies, Press Release Date: Jul. 8, 2019, (https:/… [cited by applicant]
PubChem, OPEN Chemistry Database, Compound Summary for CID-22036753, pp. 4, (2007), 12 pages. [cited by applicant]
Rainer, M.K., “Risperidone Long-acting Injection: A Review of its Long Term Safety and Efficacy,” [cited by applicant]
Rummel et al., “Antidepressants as Add-on Treatment to Antipsychotics for People with Schizophrenia and Pronounced Negative Symptoms: A Systematic Review of Randomized Trials,” Schizophrenia Res., vol. 80, p. 85-97 (200… [cited by applicant]
Savjani, et al., “Drug Solubility: Importance and Enhancement Techniques,” [cited by applicant]
Schennach, et al., “What Are Residual Symptoms in Schizophrenia Spectrum Disorder? Clinical Description and 1-year Persistence Within a Naturalistic Trial,” [cited by applicant]
Sepehry et al., “Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia: A Meta-Analysis,” J. Clin. Psychiatry, vol. 68, No. 4, p. 604-610 (2007). [cited by applicant]
Silver et al., “Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?,” Neurotherapeutics, vol. 6, p. 8… [cited by applicant]
Singh et al., “Efficacy of Antidepressants in Treating the Negative Symptoms of Chronic Schizophrenia: Meta-Analysis,” The British Journal of Psychiatry, vol. 197, p. 174-179 (2010). [cited by applicant]
Smith et al., “Schizophrenia (Maintenance Treatment),” Clinical Evidence, 04: 1007 (2009). [cited by applicant]
Snyder, et al., “Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission,” [cited by applicant]
Timmins, G.S., “Deuterated drugs: where are we now?” [cited by applicant]
Tohen, M., et al., “Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression,” Arch Gen Psychiatry, vol. 60, pp. 1079-1088, (2003). [cited by applicant]
Tonn, G.R., et al., “Simultaneous Analysis of Diphenhydramine and a Stable Isotope Analog (2H10)Diphenhydramine Using Capillary Gas Chromatography with Mass Selective Detection in Biological Fluids from Chronically Inst… [cited by applicant]
Vanover, et al., “A Novel Approach to Address an Unmet Need in the Treatment of Schizophrenia and Depression: Lumateperone, an Innovative Modulator of Dopamine, Serotonin, and Glutamate,” Abstract presented at the Ameri… [cited by applicant]
Vanover et al., Abstracts of the 13th International Congress on Schizophrenia (ICOSR) (Apr. 2-6, 2011), Schizophrenia Bull. 37 Suppl. 1., p. 325 (Mar. 2011). [cited by applicant]
Vanover, K., et al., “ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses,” International Clinical Psychopharamcology, vol. 26, e56, 1 page, (2011). [cited by applicant]
Vyas, P., et al., “An Evaluation of Lumateperone Tosylate for the Treatment of Schizophrenia,” Expert Opinion on Pharmacotherapy, vol. 21, No. 2, pp. 139-145, (2020); https://doi.org/10.1080/14656566.2019.1695778. [cited by applicant]
Wolen, R. L., “The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence,” J. Clin. Pharmacol., vol. 26, pp. 419-424, (1986). [cited by applicant]
Zhang, et al., “The Role of Serotonin 5-HT2A Receptors in Memory and Cognition,” [cited by applicant]
Zhang et al., “Alterations of Amplitude of Low-Frequency Fluctuation in Treatment-Resistant Versus Non-Treatment-Resistant Depression Patients,” Neuropsychiatric Disease and Treatment, vol. 2019, No. 15, p. 2119-2128 (2… [cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Additional Results from Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia,” Intra-Cellular Therapies, Press Release Date: N… [cited by applicant]